KC
ALNY icon

Kepos Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kepos Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,860
Closed -$1.39M – 341
2018
Q3 		$1.39M Hold
15,860
– – 0.07% 198
2018
Q2 		$1.56M Buy
+15,860
New +$1.57M 0.08% 184

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Kepos Capital's ALNY Position: Q4 2018 in Review

Kepos Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 15,860 shares — an estimated $1.39M sold.

Kepos Capital first reported a position in ALNY in Q2 2018 and held it in 2 quarters. The position peaked at $1.56M in Q2 2018. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Kepos Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Kepos Capital sold 15,860 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $1.39M.
  • Kepos Capital first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Kepos Capital's Alnylam Pharmaceuticals position peaked at $1.56M in Q2 2018.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.